156 related articles for article (PubMed ID: 15321992)
21. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
22. Intracellular location of mycoplasmas in cultured cells demonstrated by immunocytochemistry and electron microscopy.
Taylor-Robinson D; Davies HA; Sarathchandra P; Furr PM
Int J Exp Pathol; 1991 Dec; 72(6):705-14. PubMed ID: 1768615
[TBL] [Abstract][Full Text] [Related]
23. Effects of Mycoplasma fermentans on the myelomonocytic lineage. Different molecular entities with cytokine-inducing and cytocidal potential.
Rawadi G; Roman-Roman S; Castedo M; Dutilleul V; Susin S; Marchetti P; Geuskens M; Kroemer G
J Immunol; 1996 Jan; 156(2):670-8. PubMed ID: 8543819
[TBL] [Abstract][Full Text] [Related]
24. Urokinase-receptor-mediated phenotypic changes in vascular smooth muscle cells require the involvement of membrane rafts.
Kiyan J; Smith G; Haller H; Dumler I
Biochem J; 2009 Oct; 423(3):343-51. PubMed ID: 19691446
[TBL] [Abstract][Full Text] [Related]
25. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
26. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor.
Albo D; Rothman VL; Roberts DD; Tuszynski GP
Br J Cancer; 2000 Aug; 83(3):298-306. PubMed ID: 10917542
[TBL] [Abstract][Full Text] [Related]
27. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.
Behrendt N; List K; Andreasen PA; Danø K
Biochem J; 2003 Apr; 371(Pt 2):277-87. PubMed ID: 12534347
[TBL] [Abstract][Full Text] [Related]
28. Assembly of urokinase receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen.
Ellis V; Whawell SA; Werner F; Deadman JJ
Biochemistry; 1999 Jan; 38(2):651-9. PubMed ID: 9888805
[TBL] [Abstract][Full Text] [Related]
29. Mhp182 (P102) binds fibronectin and contributes to the recruitment of plasmin(ogen) to the Mycoplasma hyopneumoniae cell surface.
Seymour LM; Jenkins C; Deutscher AT; Raymond BB; Padula MP; Tacchi JL; Bogema DR; Eamens GJ; Woolley LK; Dixon NE; Walker MJ; Djordjevic SP
Cell Microbiol; 2012 Jan; 14(1):81-94. PubMed ID: 21951786
[TBL] [Abstract][Full Text] [Related]
30. Urokinase-type plasminogen activator.
Crippa MP
Int J Biochem Cell Biol; 2007; 39(4):690-4. PubMed ID: 17118695
[TBL] [Abstract][Full Text] [Related]
31. Regulation of human squamous cell carcinoma plasma membrane associated urokinase plasminogen activator by epidermal growth factor.
Niedbala MJ; Bajetta S; Carbone R; Sartorelli AC
Cancer Commun; 1990; 2(9):317-24. PubMed ID: 2169831
[TBL] [Abstract][Full Text] [Related]
32. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
Allan EH; Martin TJ
J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
[TBL] [Abstract][Full Text] [Related]
33. Choline-containing lipids in mycoplasmas.
Rottem S
Microbes Infect; 2002 Jul; 4(9):963-8. PubMed ID: 12106789
[TBL] [Abstract][Full Text] [Related]
34. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
Biliran H; Sheng S
Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384
[TBL] [Abstract][Full Text] [Related]
35. Fusion of Mycoplasma fermentans strain incognitus with T-lymphocytes.
Franzoso G; Dimitrov DS; Blumenthal R; Barile MF; Rottem S
FEBS Lett; 1992 Jun; 303(2-3):251-4. PubMed ID: 1607025
[TBL] [Abstract][Full Text] [Related]
36. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
[TBL] [Abstract][Full Text] [Related]
37. Identification of phosphocholine-containing glycoglycerolipids purified from Mycoplasma fermentans-infected human helper T-cell culture as components of M. fermentans.
Matsuda K; Harasawa R; Li JL; Kasama T; Taki T; Handa S; Yamamoto N
Microbiol Immunol; 1995; 39(5):307-13. PubMed ID: 7565170
[TBL] [Abstract][Full Text] [Related]
38. Mycoplasma fermentans infection induces human necrotic neuronal cell death via IFITM3-mediated amyloid-β (1-42) deposition.
Sim KY; Byeon Y; Bae SE; Yang T; Lee CR; Park SG
Sci Rep; 2023 Apr; 13(1):6864. PubMed ID: 37100873
[TBL] [Abstract][Full Text] [Related]
39. Factors influencing the cell adhesion and invasion capacity of Mycoplasma gallisepticum.
Fürnkranz U; Siebert-Gulle K; Rosengarten R; Szostak MP
Acta Vet Scand; 2013 Sep; 55(1):63. PubMed ID: 24011130
[TBL] [Abstract][Full Text] [Related]
40. The physico-chemical characteristics of the phosphocholine-containing glycoglycerolipid MfGL-II govern the permeability properties of Mycoplasma fermentans.
Ben-Menachem G; Byström T; Rechnitzer H; Rottem S; Rilfors L; Lindblom G
Eur J Biochem; 2001 Jul; 268(13):3694-701. PubMed ID: 11432735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
